Laurion Capital Management LP lessened its stake in shares of Aptinyx Inc (NASDAQ:APTX) by 64.1% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 89,800 shares of the company’s stock after selling 160,200 shares during the quarter. Laurion Capital Management LP owned about 0.27% of Aptinyx worth $2,601,000 at the end of the most recent reporting period.
Several other large investors also recently modified their holdings of APTX. Frazier Management LLC purchased a new stake in shares of Aptinyx during the 2nd quarter worth approximately $77,104,000. Partner Fund Management L.P. purchased a new stake in shares of Aptinyx during the 2nd quarter worth approximately $32,072,000. BlackRock Inc. lifted its position in shares of Aptinyx by 1,822.7% during the 3rd quarter. BlackRock Inc. now owns 769,072 shares of the company’s stock worth $22,272,000 after buying an additional 729,072 shares during the last quarter. NF Trinity Capital Hong Kong Ltd purchased a new stake in shares of Aptinyx during the 2nd quarter worth approximately $17,121,000. Finally, Victory Capital Management Inc. purchased a new stake in shares of Aptinyx during the 2nd quarter worth approximately $16,984,000. Institutional investors and hedge funds own 64.76% of the company’s stock.
Separately, Cantor Fitzgerald initiated coverage on shares of Aptinyx in a research report on Wednesday, November 14th. They set an “overweight” rating and a $40.00 price objective for the company. Five research analysts have rated the stock with a buy rating, Aptinyx currently has an average rating of “Buy” and an average price target of $34.25.
Shares of NASDAQ:APTX opened at $21.35 on Friday. Aptinyx Inc has a twelve month low of $17.35 and a twelve month high of $32.25.
Aptinyx (NASDAQ:APTX) last issued its quarterly earnings data on Tuesday, November 13th. The company reported ($0.43) earnings per share for the quarter, topping the consensus estimate of ($1.01) by $0.58. The company had revenue of $0.94 million for the quarter, compared to analysts’ expectations of $1.10 million. On average, sell-side analysts forecast that Aptinyx Inc will post -2.33 earnings per share for the current fiscal year.
Aptinyx Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. It is developing NYX-2925 that is in Phase II clinical trial for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II exploratory clinical trial for fibromyalgia; and NYX-783, an NMDAr receptor that is in Phase I clinical trial for the treatment of post-traumatic stress disorder.
See Also: Preferred Stock
Receive News & Ratings for Aptinyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptinyx and related companies with MarketBeat.com's FREE daily email newsletter.